General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Harvoni (ledipasvir/sofosbuvir)
Status:
Concluded with an LOI
Manufacturer:
Gilead Sciences Canada Inc.
Indication:
Chronic Hepatitis C
Last updated February 17, 2017
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Chronic Hepatitis C
Last updated February 17, 2017
Epclusa (sofosbuvir/velpatasvir)
Status:
Concluded with an LOI
Manufacturer:
Gilead Sciences Canada Inc.
Indication:
Chronic Hepatitis C
Last updated February 17, 2017
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Chronic Hepatitis C
Last updated February 17, 2017
Zepatier (elbasvir/grazoprevir)
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Chronic Hepatitis C
Last updated February 17, 2017
Technivie (ombitasvir/paritaprevir/ritonavir)
Status:
Concluded without agreement
Manufacturer:
AbbVie Corporation
Indication:
Chronic Hepatitis C (genotype 4)
Last updated February 17, 2017
Status:
Concluded with an LOI
Manufacturer:
Gilead Sciences Canada Inc.
Indication:
Chronic Hepatitis C
Last updated February 17, 2017
Plegridy (peginterferon beta-1a)
Status:
Concluded with an LOI
Manufacturer:
Biogen Canada Inc.
Indication:
Multiple Sclerosis, Relapsing
Last updated February 14, 2017
Status:
Concluded without agreement
Manufacturer:
Alexion Pharma GmbH
Indication:
Pediatric-onset hypophosphatasia
Last updated February 9, 2017
Status:
Negotiations were not pursued
Manufacturer:
BioMarin Pharmaceutical Inc.
Indication:
Mucopolysaccharidosis VI
Last updated January 31, 2017